Avalyn Pharma Inc. Common Stock AVLN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T16:03:52.582Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T16:02:41.492908311Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T16:01:28.559412+00:00
Avalyn Pharma Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 33.98 | 75.5% | 13.9% | 26.74 | 82.1% | 13.1% |
| 25Δ | 33.41 | 75.2% | 12.5% | 27.39 | 79.7% | 11.3% |
| 30Δ | 32.84 | 74.9% | 11.1% | 28.05 | 77.2% | 9.6% |
| 35Δ | 32.28 | 74.6% | 9.7% | 28.70 | 74.7% | 7.9% |
| 40Δ | 31.71 | 74.3% | 8.3% | 29.36 | 72.2% | 6.1% |
| 45Δ | 31.14 | 74.0% | 6.9% | 30.01 | 69.8% | 4.4% |
| 50Δ | 30.57 | 73.7% | 5.4% | 30.53 | 69.3% | 4.0% |
| 55Δ | 30.00 | 73.4% | 4.0% | 31.05 | 68.9% | 3.5% |
| 60Δ | 28.89 | 89.7% | 3.7% | 31.57 | 68.4% | 3.1% |
| 65Δ | 27.78 | 106.1% | 3.4% | 32.10 | 68.0% | 2.6% |
| 70Δ | 26.66 | 122.5% | 3.0% | 32.62 | 67.5% | 2.2% |
| 75Δ | 25.55 | 138.9% | 2.7% | 33.14 | 67.1% | 1.8% |
| 80Δ | 24.44 | 155.3% | 2.4% | 33.66 | 66.6% | 1.3% |
20Δ
- Pseudo strike
- 33.98
- IV
- 75.5%
- B/E move
- 13.9%
- Pseudo strike
- 26.74
- IV
- 82.1%
- B/E move
- 13.1%
25Δ
- Pseudo strike
- 33.41
- IV
- 75.2%
- B/E move
- 12.5%
- Pseudo strike
- 27.39
- IV
- 79.7%
- B/E move
- 11.3%
30Δ
- Pseudo strike
- 32.84
- IV
- 74.9%
- B/E move
- 11.1%
- Pseudo strike
- 28.05
- IV
- 77.2%
- B/E move
- 9.6%
35Δ
- Pseudo strike
- 32.28
- IV
- 74.6%
- B/E move
- 9.7%
- Pseudo strike
- 28.70
- IV
- 74.7%
- B/E move
- 7.9%
40Δ
- Pseudo strike
- 31.71
- IV
- 74.3%
- B/E move
- 8.3%
- Pseudo strike
- 29.36
- IV
- 72.2%
- B/E move
- 6.1%
45Δ
- Pseudo strike
- 31.14
- IV
- 74.0%
- B/E move
- 6.9%
- Pseudo strike
- 30.01
- IV
- 69.8%
- B/E move
- 4.4%
50Δ
- Pseudo strike
- 30.57
- IV
- 73.7%
- B/E move
- 5.4%
- Pseudo strike
- 30.53
- IV
- 69.3%
- B/E move
- 4.0%
55Δ
- Pseudo strike
- 30.00
- IV
- 73.4%
- B/E move
- 4.0%
- Pseudo strike
- 31.05
- IV
- 68.9%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 28.89
- IV
- 89.7%
- B/E move
- 3.7%
- Pseudo strike
- 31.57
- IV
- 68.4%
- B/E move
- 3.1%
65Δ
- Pseudo strike
- 27.78
- IV
- 106.1%
- B/E move
- 3.4%
- Pseudo strike
- 32.10
- IV
- 68.0%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- 26.66
- IV
- 122.5%
- B/E move
- 3.0%
- Pseudo strike
- 32.62
- IV
- 67.5%
- B/E move
- 2.2%
75Δ
- Pseudo strike
- 25.55
- IV
- 138.9%
- B/E move
- 2.7%
- Pseudo strike
- 33.14
- IV
- 67.1%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 24.44
- IV
- 155.3%
- B/E move
- 2.4%
- Pseudo strike
- 33.66
- IV
- 66.6%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 59.54% | |
| 60.01% | |
| 59.44% | |
| 61.16% | |
| 77.81% | |
| 79.70% | |
| 79.18% | |
| 71.43% | |
| 84.78% |
Biotechnology
AVTX
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly…
More →AVXL
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
More →AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is…
More →BBIO
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
More →BCAX
Description unavailable
More →BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is…
More →